Cecilia Larocca is a Dermatology physician. OpenAlex indexes 81 publications with 1,534 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
218 N Charles St
Apt. 1511
Baltimore, MD 212014021
Telephone
646-483-8936Registry record last updated 27 Mar 2018.
Clinical trials
- A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- KYOWA KIRIN, INC.Program year20254 payments
- Kyowa Kirin, Inc.Program year20244 payments
- Kyowa Kirin, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
25.3%Corticosteroid12.2%Triamcinolone Acetonide100%Part D≥26 patientsAntivirals7.8%Imiquimod100%Part D≥12 patients+ 1 more class in this area
Cancer & immunology
23.3%Nucleoside Metabolic Inhibitor9.5%Fluorouracil100%Part D≥24 patientsRetinoid5.4%Bexarotene100%Part D<11 patients+ 2 more classes in this area
Sensory organs
17.9%Corticosteroid17.9%Clobetasol Propionate62%Betamethasone Diprop Augmented38%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Increasing incidence of cutaneous T-cell lymphoma among children and young adults in the United States, 1997-2019: A national poplation-based study using the National Childhood Cancer Registry
Journal of the American Academy of Dermatology
2026 - 61342 Generation of Concepts for a Core Domain Set to Assess Health-Related Quality of Life in Patients with Cutaneous T-Cell Lymphoma: a Mixed Methods Study
Journal of the American Academy of Dermatology
2025 - Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
Journal for ImmunoTherapy of Cancer
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”